Prednikarbat GALEN (Prednicarbate) 2.5 mg/g Ointment
Moderately potent topical corticosteroid for inflammatory skin conditions such as eczema, dermatitis and psoriasis
Prednikarbat GALEN is an ointment containing the active substance prednicarbate at a strength of 2.5 mg/g (0.25%). Prednicarbate is a non-halogenated synthetic corticosteroid classified as moderately potent (Group II in Europe, Class 5 in the United States). It is used to treat inflammatory, itchy, and scaly skin conditions that respond to corticosteroid therapy, such as atopic dermatitis, contact dermatitis, psoriasis, and certain forms of eczema. The ointment formulation is particularly suited to dry, cracked, and lichenified skin. This guide explains how it works, how to use it correctly, potential side effects, and important safety considerations in line with current international dermatology guidelines.
Quick facts about Prednikarbat GALEN
Key takeaways about Prednikarbat GALEN
- Moderately potent topical steroid: Prednicarbate is classified as Group II in Europe (Class 5 in the US). It offers effective relief of itching and inflammation while producing less skin thinning than many older corticosteroids.
- Apply thinly, once or twice daily: A thin layer rubbed gently into affected skin is all that is required. More ointment does not mean faster healing – it only increases the risk of side effects.
- Limit duration of use: Treatment should usually not exceed 2 to 4 weeks in adults, or 1 to 2 weeks in children, without medical reassessment. Gradual step-down is preferred to abrupt stopping in chronic eczema.
- Avoid face, folds and occlusion unless advised: The face, eyelids, armpits, groin and skin under nappies absorb much more medicine and are more prone to atrophy. Do not cover with airtight dressings unless your doctor tells you to.
- Not for infected or broken skin alone: Prednicarbate does not treat infections. If the skin looks infected (weeping, crusting, fever, spreading redness), contact your doctor – an antibiotic or antifungal may also be required.
What Is Prednikarbat GALEN and What Is It Used For?
Prednikarbat GALEN is a prescription ointment containing prednicarbate 2.5 mg/g. It is a moderately potent (Group II) topical corticosteroid used to reduce inflammation, redness, swelling, and itching in a range of skin conditions that respond to corticosteroid therapy.
Topical corticosteroids are among the most widely prescribed medicines in dermatology. They have been the mainstay of treatment for inflammatory skin conditions for more than six decades. Prednicarbate was developed in the 1980s as part of a new generation of so-called "soft" or "non-halogenated" corticosteroids designed to retain strong anti-inflammatory activity while reducing the typical local side effects of older fluorinated steroids, particularly skin atrophy.
Prednicarbate is a double-ester molecule that is activated and simultaneously inactivated within the skin. Once applied, it enters the epidermis and is rapidly metabolised by cutaneous esterases to prednisolone 17-ethylcarbonate (its main active metabolite) and eventually to inactive breakdown products. This rapid local metabolism is the main reason why prednicarbate is considered to have a favourable benefit-risk ratio compared with many older topical corticosteroids of similar potency, such as betamethasone valerate.
At the cellular level, the active metabolite binds to glucocorticoid receptors inside skin cells. This complex then moves into the cell nucleus and alters gene transcription. The result is reduced production of pro-inflammatory cytokines, chemokines, prostaglandins and leukotrienes, and reduced recruitment of inflammatory cells into the skin. Clinically, this translates into less redness, less swelling, less itching, and less scaling.
Approved and Common Uses
Prednikarbat GALEN ointment is indicated for inflammatory and itchy (pruritic) skin disorders that are known to respond to corticosteroid treatment. Typical indications include:
- Atopic dermatitis (atopic eczema): A chronic, relapsing inflammatory skin condition characterised by dry, itchy, red patches, often on flexural areas (elbow creases, behind the knees, wrists and neck). Prednicarbate is used during flare-ups to gain control of inflammation.
- Contact dermatitis: Both allergic contact dermatitis (e.g. reactions to nickel, fragrances, preservatives, or plant allergens) and irritant contact dermatitis (e.g. from soaps, detergents, or repeated water exposure).
- Discoid (nummular) eczema: Round or oval coin-shaped patches of itchy, inflamed skin, often on the arms and legs.
- Seborrhoeic dermatitis: Scaly, red, itchy patches on sebum-rich areas such as the scalp, face, chest and upper back. Caution is required on the face – short courses only.
- Psoriasis (limited plaque disease): Particularly on the trunk and limbs. Not recommended for widespread, pustular, or erythrodermic psoriasis, which require specialist care.
- Lichen simplex chronicus and prurigo: Thickened, leathery, intensely itchy skin that has developed as a result of chronic scratching or rubbing.
- Lichen planus and other lichenoid dermatoses: Purple, flat-topped, itchy papules, typically on the wrists, ankles and lower back.
- Other inflammatory dermatoses considered by the prescribing physician to respond to a moderately potent topical corticosteroid.
Why the Ointment Formulation Matters
Prednikarbat GALEN is supplied as an ointment, which is a greasy, occlusive, water-free or low-water formulation. Compared with creams, gels and lotions, ointments have specific advantages for certain types of skin disease:
- Better moisturisation: The occlusive film traps water in the stratum corneum, helping to restore the skin barrier in dry, chapped or cracked skin.
- Enhanced corticosteroid penetration: Ointments generally enhance the penetration and potency of the same corticosteroid compared with cream formulations, which is useful on thickened (lichenified) plaques.
- Fewer preservatives and fewer contact allergens: Because ointments contain little or no water, they rarely need preservatives, which lowers the risk of triggering allergic contact dermatitis from the vehicle itself.
Ointments are less suitable for very moist, weeping skin, intertriginous areas (skin folds such as groin and armpits), hairy areas, and hot climates, where they may feel unpleasant or trap heat. In those situations a cream or lotion formulation may be preferred.
Always use Prednikarbat GALEN exactly as prescribed by your doctor. Do not apply it to any skin problem that has not been assessed by a healthcare professional. Topical corticosteroids can worsen fungal, viral, or bacterial skin infections if used alone, and they can mask the signs of underlying skin cancer or other serious conditions.
What Should You Know Before Using Prednikarbat GALEN?
Before starting Prednikarbat GALEN, tell your doctor about any skin conditions, infections, allergies and other medicines you use. Although topical corticosteroids are usually safe when used correctly for short periods, there are specific situations in which this ointment should be avoided or used with extra caution.
Contraindications
Do not use Prednikarbat GALEN if any of the following applies to you:
- You are allergic to prednicarbate, other corticosteroids, or any of the excipients in the ointment.
- You have a bacterial skin infection (such as impetigo or erysipelas) at the intended treatment site, unless you are simultaneously receiving adequate anti-infective treatment.
- You have a viral skin infection, including herpes simplex (cold sores, genital herpes), varicella-zoster (chickenpox, shingles), or molluscum contagiosum.
- You have a fungal skin infection such as tinea (ringworm), candidiasis, or pityriasis versicolor at the treatment site.
- The skin shows specific reactions following vaccination, such as cowpox-like vaccination reactions.
- You have syphilitic or tuberculous skin lesions at the application site.
- You have rosacea or perioral dermatitis, because topical corticosteroids can precipitate or severely worsen these conditions.
- You have acne vulgaris, which may flare under corticosteroid influence.
Prednikarbat GALEN is for external skin use only. Do not apply it inside the eyes, mouth, nose, or any other mucous membrane. If the ointment accidentally gets into your eyes, rinse thoroughly with plenty of clean water and seek medical advice if irritation persists. Long-term periocular application has been linked to glaucoma and cataracts.
Warnings and Precautions
Inform your doctor before using Prednikarbat GALEN if any of the following applies to you. You may still be able to use the ointment, but your treatment plan may require modifications such as shorter duration, smaller treated area, avoidance of occlusion, or close monitoring:
- Application on the face, eyelids, armpits, groin, or genitals: Skin in these areas is thinner and absorbs more medicine. Short courses (generally no more than 5 to 7 days), the smallest effective amount, and avoidance of continuous daily use are recommended.
- Use in infants and young children: Children have a higher body-surface-area-to-weight ratio than adults, and their skin absorbs topical corticosteroids proportionally more. Duration of treatment must be kept as short as possible, and occluded areas (nappy area, skin folds) must be avoided whenever possible.
- Use on large surface areas: Applying any moderately potent topical steroid to extensive areas (for instance, more than 10-20% of the body surface) increases the risk of systemic absorption. Dose, duration, and body coverage should always be kept to the minimum necessary.
- Use under airtight dressings (occlusion): Bandages, plastic wrap, or nappies act as occlusive dressings and can dramatically increase absorption and local side effects. Occlusion should only be used on explicit medical advice.
- Pre-existing skin atrophy: If your skin is already thin or fragile (for instance, following long-term steroid use or in older adults), additional corticosteroid exposure may worsen atrophy, telangiectasias or striae.
- Chronic leg ulcers: Topical corticosteroids can delay wound healing and should generally be avoided on ulcerated skin.
- Concomitant skin infection: If there is any doubt about infection, your doctor may prescribe a combined preparation (corticosteroid plus antibiotic or antifungal) or treat the infection first.
- Glaucoma or cataracts: Long-term application to the eyelids or periocular region has been associated with increased intraocular pressure, glaucoma and cataract formation, particularly in predisposed individuals.
- Pituitary-adrenal (HPA) axis suppression: Extensive or prolonged application, especially under occlusion or in children, can cause enough systemic absorption to temporarily suppress the body’s natural cortisol production.
If your skin condition does not improve after 2 weeks of treatment, or if it worsens, contact your doctor. The diagnosis may need to be reconsidered or an infection ruled out.
After prolonged, high-potency, or repeated topical corticosteroid use – particularly on the face or genital area – some patients develop "topical steroid withdrawal" when the medication is stopped, characterised by intense redness, burning, flaking and rebound flares. This is rare with short, appropriate courses of moderately potent agents such as prednicarbate, but it is a reason to avoid indefinite daily use without medical review.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, are planning to become pregnant, or are breastfeeding, tell your doctor before using Prednikarbat GALEN. The decision to use any topical corticosteroid during pregnancy should always be made by a healthcare professional who has weighed the benefits against the potential risks.
Pregnancy: Systematic reviews and large cohort studies suggest that mild-to-moderate potency topical corticosteroids used in pregnancy are not clearly associated with major birth defects, preterm birth, or fetal death. However, large cumulative doses (more than approximately 300 g of potent or very potent corticosteroid during the whole pregnancy) have been linked in some studies to low birth weight. Therefore, during pregnancy, topical corticosteroids including prednicarbate should be used on the smallest effective area, for the shortest time possible, and preferably without occlusion.
Breastfeeding: It is not known to what extent prednicarbate, applied to the skin, passes into breast milk. To be safe, do not apply Prednikarbat GALEN on the chest or breast area if you are breastfeeding, as direct contact with the infant’s mouth should be avoided. Also wash your hands carefully after applying the ointment elsewhere before handling your baby.
Driving and Using Machines
Prednikarbat GALEN has no known effect on the ability to drive or operate machinery. Topical corticosteroids do not cause drowsiness, dizziness or blurred vision when used correctly on the skin.
How Does Prednikarbat GALEN Interact with Other Drugs?
Clinically significant drug interactions with topical prednicarbate are uncommon because very little of the medication reaches the bloodstream under normal conditions of use. However, there are several situations – and some drug categories – where the combination with prednicarbate still deserves caution.
The systemic absorption of prednicarbate from intact skin is low, typically in the order of 1 to 3% after single application. Absorption rises sharply when the ointment is applied to inflamed, damaged, or broken skin, under occlusion, on thin skin (face, eyelids, genitals), on large body surface areas, or in infants. Under these circumstances, systemic drug interactions that are normally only relevant for oral corticosteroids become theoretically relevant.
Major Interactions
| Drug / Class | Interaction Effect | Clinical Significance |
|---|---|---|
| Other topical corticosteroids (creams, lotions, scalp solutions, inhaled or intranasal steroids) | Cumulative corticosteroid exposure, increasing the risk of both local and systemic side effects | Moderate – avoid overlapping corticosteroid products on the same skin area; inform your doctor about all steroid preparations you use. |
| Live attenuated vaccines (MMR, varicella, yellow fever, BCG, oral polio) | In theory, very extensive or long-term prednicarbate use could blunt the immune response; risk is minimal with typical topical use | Low to moderate – discuss scheduling of live vaccines with your doctor if you are using large amounts of topical corticosteroid. |
| Strong CYP3A4 inhibitors (ritonavir, cobicistat, itraconazole, ketoconazole, clarithromycin) | May theoretically increase systemic exposure to the active metabolite prednisolone 17-ethylcarbonate when absorption is high (occlusion, extensive use) | Low – relevant only with extensive or prolonged topical use; clinically significant interactions have not been reported with standard ointment use. |
| Other immunosuppressants (ciclosporin, tacrolimus, methotrexate, biologic agents) | Additive immunosuppression; possible increased risk of skin infections at application site | Moderate – your dermatologist will weigh the benefit of combining agents in severe eczema or psoriasis. |
| Systemic corticosteroids (oral prednisolone, dexamethasone, etc.) | Additive risk of HPA axis suppression, hyperglycaemia, osteoporosis and other systemic steroid effects | Moderate – inform your doctor about any oral or injected corticosteroid use to avoid cumulative systemic exposure. |
Minor or Theoretical Interactions
| Drug / Situation | Effect | Advice |
|---|---|---|
| Topical calcineurin inhibitors (tacrolimus, pimecrolimus) | Often used sequentially with topical steroids in atopic eczema; possible local irritation when rotated | Use exactly as your dermatologist instructs; typically one in the morning and the other in the evening, or alternating days. |
| Emollients and moisturisers | Highly recommended alongside prednicarbate to improve skin barrier function; do not reduce its effect when applied at different times | Apply emollients liberally at least twice daily; wait about 15 minutes before applying the corticosteroid ointment on the same area. |
| Antiseptic washes and antibacterial soaps | May help with superinfected eczema but can also dry out the skin | Use as directed by your doctor; avoid harsh soaps on affected areas. |
| Phototherapy (UVB, PUVA) | Sometimes combined with topical steroids in psoriasis; order of application matters | Apply the ointment after phototherapy sessions, not before, unless specifically instructed. |
| Non-prescription cosmetic products | Potential for irritation or allergic contact dermatitis, particularly from fragrances and preservatives | Avoid applying cosmetics, perfumes or scented lotions on areas being treated with prednicarbate. |
This is not an exhaustive list. Always tell your doctor or pharmacist about all medicines you are taking or have recently taken, including prescription medicines, over-the-counter products, vitamins and herbal supplements, so they can check for possible interactions specific to your situation.
What Is the Correct Dosage of Prednikarbat GALEN?
Apply a thin layer of Prednikarbat GALEN to the affected skin once or twice a day. Use the smallest effective amount for the shortest possible time. Your doctor will tell you exactly how often, for how long, and on which areas to use the ointment, based on your condition and your age.
The goal of topical corticosteroid therapy is to bring inflammation and itching under control as quickly as possible, then to step down to less potent treatment or to stop altogether, often combined with a long-term emollient routine. The following information is general – always follow your prescriber’s instructions.
Adults and Adolescents (12 years and older)
Standard dosing
Apply a thin layer of ointment once or twice daily to affected areas of skin. Rub in gently until the ointment is fully absorbed. A practical guide for dosing is the fingertip unit (FTU): one FTU is the amount of ointment squeezed from a standard 5 mm nozzle along an adult index finger from the tip to the first crease, and is enough to cover an area about twice the size of the palm of a flat hand.
Treatment duration
Continuous use should generally not exceed 2 to 4 weeks without medical reassessment. Once the condition improves, many dermatologists recommend stepping down to intermittent application (for example, two days a week on previously affected areas) as part of a proactive maintenance strategy for chronic eczema, combined with daily emollient use.
Infants and Children
Children 4 months to 11 years
Prednikarbat GALEN may be used in children if specifically prescribed by a doctor. Application should be limited to small, clearly defined areas, once a day, and generally for no more than 1 to 2 weeks. Use on the face, nappy area, and skin folds should be avoided unless specifically authorised by a dermatologist. Growth and general health should be monitored when topical corticosteroids are used regularly over longer periods in children.
Infants under 4 months
Use in infants younger than 4 months is generally not recommended because their skin is particularly thin and absorbs more of the medication relative to their body weight. If treatment is considered necessary, it should only be prescribed and supervised by a paediatrician or dermatologist.
Elderly Patients
Age-related considerations
Older adults often have thinner skin and a more fragile skin barrier, which increases susceptibility to skin atrophy, striae, telangiectasias and bruising. Use the lowest effective amount, apply once daily where possible, and reassess the need for treatment at least every 1-2 weeks. Emollients are particularly important in this age group.
Fingertip Unit (FTU) Guidance
To help patients use the correct amount of ointment, dermatologists commonly refer to fingertip units. The table below gives approximate FTUs needed to cover typical body regions in adults. Halve these amounts for school-age children and reduce further for infants.
| Body Region | FTU (one application) | Approximate Weight (g) |
|---|---|---|
| Face and neck | 2.5 FTU | ~1.25 g |
| One hand (both sides) | 1 FTU | ~0.5 g |
| One entire arm | 3 FTU | ~1.5 g |
| One foot | 2 FTU | ~1 g |
| One entire leg | 6 FTU | ~3 g |
| Front of trunk (chest and abdomen) | 7 FTU | ~3.5 g |
| Back and buttocks | 7 FTU | ~3.5 g |
Missed Dose
If you forget to apply the ointment, do so as soon as you remember. However, if it is almost time for your next dose, simply skip the missed dose and continue with your regular schedule. Do not apply a double amount to make up for a missed application; applying more ointment at once does not improve your condition and can increase the risk of side effects.
Overdose
An acute overdose is very unlikely with a topical ointment. Applying a larger amount than prescribed on a single occasion is not generally harmful, but sustained overuse – particularly in large amounts, on large surface areas, under occlusion, or for long periods – can lead to local side effects such as skin thinning and striae, and in rare cases to systemic corticosteroid effects including suppression of the body’s natural cortisol production.
If you suspect that the ointment has been swallowed accidentally (for example, by a child), contact your national poison information centre or seek medical advice. Accidental ingestion of a small amount is unlikely to cause serious harm, but ingestion of larger quantities may cause short-lived systemic corticosteroid effects such as elevated blood sugar and temporary adrenal suppression.
If you have been using Prednikarbat GALEN every day for many weeks on large areas of the body, do not stop suddenly. Speak to your doctor about a gradual step-down (e.g. alternate-day application, then twice-weekly, combined with continued emollient use) to reduce the risk of a rebound flare and, in rare cases, of systemic withdrawal symptoms.
What Are the Side Effects of Prednikarbat GALEN?
Like all medicines, Prednikarbat GALEN can cause side effects, although not everybody gets them. Most side effects are local (affecting the treated skin), mild, and reversible when the ointment is stopped. Systemic side effects are rare with short-term, appropriate use.
Clinical studies of prednicarbate have consistently shown that it produces significantly less skin atrophy than many older moderately potent topical corticosteroids, such as betamethasone valerate, when used for similar durations. Nevertheless, any topical corticosteroid can produce skin changes with prolonged use, especially on delicate areas such as the face, eyelids, and skin folds.
- Swelling of the face, lips, tongue or throat; hives spreading over the body; difficulty breathing or swallowing (signs of severe allergic reaction / anaphylaxis).
- Rapidly spreading redness, pain, fever, pus or red streaks at the application site (possible serious skin infection).
- Severe or worsening burning, blistering, or peeling of the treated skin.
- Signs of systemic corticosteroid effects after very extensive or prolonged use, such as unusual weight gain, rounded face, high blood pressure or high blood sugar.
Common Side Effects
- Transient burning or stinging on application
- Itching at the application site
- Skin dryness or irritation
- Folliculitis (inflammation of hair follicles, small red bumps)
- Mild redness different from the underlying dermatitis
Uncommon Side Effects
- Skin atrophy (thinning) with prolonged use
- Striae distensae (stretch marks), particularly in skin folds
- Telangiectasias (visible small blood vessels)
- Changes in pigmentation (hypo- or hyperpigmentation)
- Acneiform eruption (acne-like papules and pustules)
- Perioral dermatitis
- Purpura (small purple spots from fragile capillaries)
- Hypertrichosis (increased fine hair at treatment site)
Rare Side Effects
- Allergic contact dermatitis to prednicarbate itself or to ointment excipients
- Rebound flare after sudden cessation of prolonged use
- Masking of cutaneous infections, allowing them to worsen unnoticed
- Periocular glaucoma or cataracts after long-term periorbital application
- Skin infections (bacterial, viral, fungal) as a consequence of local immunosuppression
Frequency Not Known
- Systemic corticosteroid effects after extensive or prolonged use, including HPA axis suppression, Cushingoid features, growth suppression in children, and hyperglycaemia
- Blurred vision
- Topical steroid withdrawal syndrome (red, burning skin after stopping long-term use)
- Exacerbation of rosacea or perioral dermatitis
- Delayed wound healing
Reporting suspected side effects after a medicine has been authorised is important for ongoing safety monitoring. Healthcare professionals and patients can report suspected adverse reactions to their national medicines agency (e.g. FDA MedWatch in the USA, the Yellow Card Scheme in the UK, EMA EudraVigilance in the EU). Reporting helps improve the safety information available for all patients.
How Should You Store Prednikarbat GALEN?
Keep Prednikarbat GALEN out of the sight and reach of children. Store the ointment in the original tube, below 25°C (77°F), and use it within the expiry date printed on the packaging. Do not freeze.
Keep the tube tightly closed when not in use to prevent drying out and contamination. Do not use the ointment after the expiry date, which refers to the last day of the month shown. Once the tube has been opened, it should generally be used within a few months – follow any specific in-use shelf life instructions included with your pack.
Do not use Prednikarbat GALEN if the ointment changes colour, develops an unusual odour, or if the tube is damaged. If the ointment separates, discolours, or looks different from how it appeared originally, consult your pharmacist.
Medicines should not be disposed of in household waste or wastewater. Ask your pharmacist how to dispose of unused or expired medicines. These measures help protect the environment and prevent accidental exposure of children or pets to active substances.
What Does Prednikarbat GALEN Contain?
Each gram of Prednikarbat GALEN ointment contains 2.5 mg of prednicarbate as the active ingredient. The remaining components are inactive excipients that together form the ointment base, protect the active substance, and determine how the product feels on the skin.
Active Substance
Prednicarbate 2.5 mg/g (0.25% w/w) – a synthetic non-halogenated double-ester corticosteroid of moderate potency. Prednicarbate is a white to almost white crystalline powder, practically insoluble in water but soluble in several organic solvents, which is why it is formulated in lipophilic ointment and cream bases.
Excipients (Inactive Ingredients)
The typical ointment base for prednicarbate 2.5 mg/g ointment contains excipients that may include:
- White soft paraffin (petrolatum) – the main occlusive ingredient that traps moisture and softens the skin.
- Liquid paraffin (mineral oil) – adjusts consistency and spreadability.
- Macrogol stearates or similar emulsifiers – help distribute the active substance evenly through the base.
- Medium-chain triglycerides – improve the skin feel and aid penetration.
- Edetic acid (EDTA) disodium salt – stabilising agent that protects the formulation from oxidative degradation.
- Purified water – present in small amounts depending on the specific ointment formulation.
The exact list of excipients can vary slightly between packs and production sites. Always refer to the printed patient information leaflet that comes with your specific tube of Prednikarbat GALEN for the definitive ingredient list. This is particularly important if you have known allergies or sensitivities to ointment constituents.
If you have previously had allergic reactions to paraffin-based ointments, macrogol ingredients, or any other excipient, let your doctor or pharmacist know before starting treatment. Allergic contact dermatitis to ointment excipients is uncommon but does occur and can be mistaken for worsening of the underlying skin condition.
Frequently Asked Questions About Prednikarbat GALEN
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources and regulatory references.
- European Medicines Agency (2024). "Summary of Product Characteristics: Prednicarbate topical preparations." Official EU regulatory source for prednicarbate. Evidence level: Regulatory
- Wollenberg A, Kinberger M, Arents B, et al. (2022). "European guideline (EuroGuiDerm) on atopic eczema: Part I – systemic therapy." Journal of the European Academy of Dermatology and Venereology, 36(9), 1409–1431. https://doi.org/10.1111/jdv.18345 European consensus guideline on atopic eczema including topical corticosteroid use. Evidence level: 1A
- Wollenberg A, Christen-Zäch S, Taieb A, et al. (2020). "ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children." Journal of the European Academy of Dermatology and Venereology, 34(12), 2717–2744. European task force position paper on atopic dermatitis management. Evidence level: 1A
- British National Formulary (2024). "Topical corticosteroids: potency classification, indications, adverse effects and counselling." BNF Topical Corticosteroids Comprehensive prescribing reference. Continuously updated evidence-based resource.
- World Health Organization (2023). "WHO Model List of Essential Medicines – 23rd List." WHO Essential Medicines List WHO framework on essential medicines including topical corticosteroids for dermatological care. Evidence level: 1A
- Korting HC, Schoellmann C, Cholcha W, Wolff H (2010). "Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial." Journal of the European Academy of Dermatology and Venereology, 24(10), 1176–1182. Reference to clinical research on eczema therapy. Evidence level: 1B
- Niedner R (1998). "Therapie mit systemischen Glukokortikoiden – eine praxisbezogene Übersicht. Part II: Topical corticosteroids." Der Hautarzt, 49(4), 332–341. Classic review of topical corticosteroid pharmacology including prednicarbate. Evidence level: 2A
- Schoepe S, Schaecke H, May E, Asadullah K (2006). "Glucocorticoid therapy-induced skin atrophy." Experimental Dermatology, 15(6), 406–420. https://doi.org/10.1111/j.0906-6705.2006.00435.x Mechanistic review of skin atrophy from topical steroids, including atrophogenic potential of prednicarbate. Evidence level: 1A
- Lubach D, Rath J, Kietzmann M (1995). "Steroid-induced skin atrophy: comparison of prednicarbate and betamethasone-17-valerate." Zeitschrift für Hautkrankheiten, 70(5), 341–344. Comparative study demonstrating prednicarbate's reduced atrophogenic effect. Evidence level: 1B
- Menter A, Strober BE, Kaplan DH, et al. (2019). "Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics." Journal of the American Academy of Dermatology, 80(4), 1029–1072. https://doi.org/10.1016/j.jaad.2018.11.057 AAD-NPF guideline on psoriasis management including topical therapy. Evidence level: 1A
- Chi CC, Wang SH, Kirtschig G, Wojnarowska F (2017). "Safety of topical corticosteroids in pregnancy." Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD007346. https://doi.org/10.1002/14651858.CD007346.pub3 Cochrane systematic review of topical corticosteroid safety in pregnancy. Evidence level: 1A
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence assessment. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomised controlled trials. All recommendations are consistent with current WHO, EMA, FDA, BNF, and EuroGuiDerm guidelines.
iMedic Editorial Standards
Peer Review Process
Every article is independently reviewed by at least two medical specialists before publication and undergoes regular re-review to ensure continued accuracy and relevance.
Fact-Checking
All medical claims are verified against primary sources including regulatory documents (EMA SmPC, FDA labels), clinical guidelines, and peer-reviewed research published in high-impact journals.
Update Frequency
Drug information is reviewed at minimum every 12 months and whenever significant new safety data, guideline updates, or regulatory changes are published.
Corrections Policy
Identified errors are corrected promptly with full transparency. Corrections are documented and the article revision date is updated accordingly.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialists who oversee all content for accuracy and adherence to international guidelines. No member has conflicts of interest with pharmaceutical companies.